Investing.com UK - Financial Markets Worldwide
Get 40% Off
Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Adamis Pharma Shares Nosedive As Its COVID-19 Candidate Shows No Efficacy

Published 21/09/2022, 14:58
© Reuters. Adamis Pharma Shares Nosedive As Its COVID-19 Candidate Shows No Efficacy

  • Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced the results from the third planned interim analysis of the Phase 2/3 clinical trial of Tempol in high-risk subjects with early COVID-19 infection.
  • The trial did not achieve its primary endpoint, as measured by comparing the rate of sustained clinical resolution of symptoms of COVID-19 at day 14 of Tempol versus placebo.
  • Last year, the company started dosing in the Phase 2/3 trial for Tempol, which was designed to enroll 248 patients.
  • The independent Data Safety Monitoring Board (DSMB) recommended that the study be halted early due to lack of efficacy.
  • The DSMB did note that no safety concerns were identified.
  • Based on the recommendation from the DSMB, the company has halted the trial. It will now evaluate the unblinded data from the trial to determine the next developmental steps for Tempol.
  • National Institutes of Health (NIH) identified Tempol as a potentially potent antiviral for COVID-19. According to a study conducted by NIH researchers, Tempol could limit the infection by impairing the activity of a viral enzyme.
  • Price Action: ADMP shares are down 45.20% at $0.20 on the last check Wednesday.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.